Suggestions
Michael Hodin
CEO, Global Coalition on Aging; Managing Partner, High Lantern Group
Michael W. Hodin, Ph.D., is a prominent figure in the fields of aging policy and strategic communications. He serves as the Managing Partner at High Lantern Group, a strategic communications firm, and is also the CEO of the Global Coalition on Aging, which advocates for effective aging policies globally.
Career Background
Hodin has an extensive background in public affairs and policy, having spent 30 years at Pfizer, Inc., where he was a senior executive responsible for international public affairs and public policy operations. His career also includes serving as a Legislative Assistant to Senator Daniel Patrick Moynihan and a Visiting Scholar at the Brookings Institution, focusing on U.S. foreign economic policy.
Education
Hodin holds a BA from Cornell University, an M.Sc. in International Relations from the London School of Economics, and both an M.Phil and a Ph.D. in Political Science from Columbia University.
Affiliations
He is a member of the Council on Foreign Relations and has held various board positions, including roles with the Foreign Policy Association and the American Society on Aging. His work emphasizes the need for global leaders to address the challenges and opportunities presented by an aging population.
Summary
Michael Hodin is recognized for his leadership in aging policy and strategic communications, leveraging his extensive experience in both the corporate and public sectors to influence how societies prepare for demographic shifts in aging.1
Highlights
On this day, February 23, 1954, America had its first mass inoculation of children with Jonas Salk’s polio vaccine, an innovation leading to one of the most important prevention actions in healthcare. Thanks to the vaccine, by the 21st century, polio cases were reduced by 99 percent worldwide. Childhood immunization has been one of the most powerful forces contributing to our 21st century longevity. Now, 70 years later, let’s join that with an equally massive and important adult immunization drive to support this century’s call to action for healthy longevity.
Policies that aim to improve the affordability of prescription medication should never jeopardize patient access and innovation. This is especially true when access threatens to exacerbate disparities. Health equity is essential to ensure that innovations reach those most in need.
Read more about how GCOA is advancing these conversations here: https://lnkd.in/eMcyab4Z
